EvlaBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EvlaBio is a private, preclinical-stage biotech addressing a critical unmet need in cardiorenal medicine: left ventricular hypertrophy in chronic kidney disease patients. The company's core asset is a highly selective anti-FGFR4 monoclonal antibody designed to block the pathological cardiac signaling driven by elevated FGF23, a hallmark of CKD. Backed by €21 million in seed funding from leading biotech VCs, EvlaBio is advancing its novel therapeutic candidate toward clinical development. The company aims to redefine treatment in a large patient population with very limited current options, targeting a key driver of cardiovascular mortality in CKD.

Cardiorenal DiseaseChronic Kidney DiseaseCardiovascular Disease

Technology Platform

Monoclonal antibody platform targeting specific pathological signaling axes; focused on inhibiting FGF23-driven activation of FGFR4 to prevent maladaptive cardiac remodeling.

Opportunities

The primary opportunity is addressing a massive, growing, and completely underserved patient population where LVH is a major cause of death.

Success could establish a new treatment paradigm in nephrocardiology.

The targeted mechanism also offers potential for expansion into other forms of cardiac hypertrophy.

Risk Factors

High translational risk that the preclinical biology may not hold in humans.

Safety risks related to disrupting FGF23's normal physiological functions.

Significant future capital requirements and competitive threats from larger players entering the space.

Competitive Landscape

The direct competitive landscape for a specific FGF23-FGFR4 inhibitor in CKD-LVH is currently sparse, representing a greenfield opportunity. However, EvlaBio competes indirectly with broad standard-of-care heart failure treatments and may face future competition from other companies targeting FGF23, phosphate metabolism, or cardiac hypertrophy through different mechanisms.

More companies in Biologics / Biosimilars →More companies in Switzerland →